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ABSTRACT
Background: Migraine is a common disabling disorder of childhood and ado-
lescence. Despite advances in the understanding of migraine pathophysiology, treat-
ment remains a challenge.
Objectives: The aims of this study were to investigate the production of nitric 
oxide synthase (NOS) enzymes in the brain stem of adolescent rats, using an experi-
mental model of migraine, and the effect of sumatriptan pretreatment on the produc-
tion of the NOS enzymes.
Methods: Male adolescent (aged ~2 months) Wistar rats were used in the study. 
The animals were anesthetized using pentobarbital. The trigeminovascular system 
was stimulated by injecting a proinflammatory molecule, carrageenan, into the cis-
terna magna of the anesthetized rats. The animals were divided into 3 groups of equal 
size: (1) the study group, in which the rats were treated with sumatriptan succinate 
2 hours before intracisternal carrageenan injection; (2) the sham group, in which the 
rats were not administered intracisternal carrageenan injection or sumatriptan pre-
treatment; and (3) the control group, in which the rats were administered intracister-
nal carrageenan injection but were not pretreated with sumatriptan. In the control 
and study groups, the rats were euthanized using ether anesthesia 1 hour after intra-
cisternal carrageenan injection. Rats in the sham group were euthanized 1 hour after 
intracisternal catheterization. Brain tissue was removed and endothelial NOS (eNOS), 
neuronal NOS (nNOS), and inducible NOS (iNOS) immunohistochemistry was 
performed.
Results: Twenty-one rats were randomized into 3 groups of 7. The mean values 
of the immunolabeling intensities for eNOS, nNOS, and iNOS enzymes in the brain 
stem were significantly lower in the sham group compared with the control group 
(P = 0.001, P = 0.002, and P = 0.001, respectively). The mean values of the immu-
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nolabeling intensities of eNOS, nNOS, and iNOS in the brain stem were significantly 
lower in the study group compared with the control group (P = 0.001, P = 0.025, 
and P = 0.005, respectively).
Conclusions: In this experimental model of migraine in adolescent rats, in-
tracisternal injection of carrageenan was associated with a significant increase in the 
production of NOS enzymes in the brain stem. Pretreatment with sumatriptan was 
associated with a decrease in NOS production. (Curr Ther Res Clin Exp. 2009;70:129– 
135) © 2009 Excerpta Medica Inc.
Key words: migraine, adolescence, carrageenan, nitric oxide synthase, 
sumatriptan.
INTRODUCTION
Migraine is a common disabling disorder (prevalence, 10%–20%) of childhood and 
adolescence.1 Despite advances in the understanding of migraine pathophysiology, 
treatment remains a challenge. Currently, treatments are classified as preventive or 
acute-attack therapies.2 Triptans have been used to treat migraines; however, these 
agents are not always effective.3 Novel therapeutic targets such as inhibitors of excit-
atory glutamatergic receptors and calcitonin gene-related peptide (CGRP) antagonists 
are currently being studied as a treatment alternative.4
In recent years, studies have reported the role of nitric oxide (NO) in headache.5–7 
Experimental evidence suggests that NO participates in vasodilatation and activation 
of the trigeminovascular system. NO has been reported to play an active role in dural 
vasodilatation, thereby contributing to the pathogenesis of migraine.6,7 An infusion 
of NO was associated with migraine-like headaches for several hours in both control 
volunteers and headache patients who fulfilled the International Headache Society 
criteria for migraine.8 The role of NO synthase (NOS) enzymes after stimulation of 
the trigeminal sensory neurons is not fully understood. However, according to a search 
of MEDLINE using the terms migraine, vascular headache, primary headache, adolescent 
animal, and adolescent rat, almost all experimental studies in the field of primary head-
ache research were performed in adult animals, and information is lacking about the 
pathophysiology of primary headaches, including migraine, in adolescent animals. 
Endothelial NOS (eNOS) and neuronal NOS (nNOS) are constitutively expressed 
in endothelial cells and neurons, respectively, and their expression is regulated at the 
transcriptional, translational, and posttranslational levels.9 Inducible NOS (iNOS) is 
the inducible isoform of NOS enzymes. The synthesis of iNOS is induced by endotoxin 
and by inflammatory cytokines in macrophages and many other cell types. A recent study 
reported iNOS expression in the central nervous system and in microglial cells.10
The 5-HT1B/1D serotonin receptor agonist, sumatriptan,
* is indicated for the treat-
ment of acute migraine attacks.3 The therapeutic action of sumatriptan is thought to 
be consistent with neuronal inhibition. Sumatriptan has been reported to inhibit neu-
*Trademark: Imigran® (GlaxoSmithKline, Brentford, United Kingdom).
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rogenic meningeal dural vasodilatation caused by electrical stimulation. This action 
was thought to occur via the inhibition of CGRP release from the trigeminal sensory 
fibers innervating the cranial blood vessels.3,11,12 Nitroglycerin-induced headache has 
been reported to respond to sumatriptan.13 It is unclear if sumatriptan has any effect 
on NOS enzymes.
The aims of this study were to investigate the production of NOS enzymes in the 
brain stem of adolescent rats, using an experimental model of migraine, and the effect 
of sumatriptan pretreatment on the production of the NOS enzymes.
MATERIALS AND METHODS
This study was approved by the ethics committee of Dokuz Eylül University School 
of Medicine, Izmir, Turkey.
Two-month-old male adolescent Wistar rats, provided by the Dokuz Eylül Univer-
sity School of Medicine, were used. The animals were housed in appropriate caging on 
a 12-hour light/dark cycle with free access to standard laboratory food and tap water. 
The animals were allowed to adjust to the housing facilities for ≥1 week before the 
study was initiated.
The rats were divided randomly into 3 groups of equal size. In the study group, 
rats were anesthetized, catheterized, and treated with intraperitoneal (IP) sumatriptan 
succinate 0.3 mg/kg 2 hours before intracisternal carrageenan injection.14 In the sham 
group, the rats were anesthetized and catheterized but were not administered intra- 
cisternal carrageenan injection or sumatriptan pretreatment. Instead of sumatriptan, 
they received the same volume of IP saline. In the control group, rats were anesthe-
tized, catheterized, and administered a 0.1-mL intracisternal carrageenan injection. 
Instead of sumatriptan, they received the same volume of IP saline. 
Animal Preparation
The animals were anesthetized with IP pentobarbital 45 mg/kg. A midline skin 
incision was made from the occipital protuberance to the cervical area. The trigemi-
novascular system was stimulated using the proinflammatory substance carrageenan 
(1 mg dissolved in 0.1 mL of saline) in the study and control groups. The carrageenan 
solution was injected into the cisterna magna using a 27-gauge needle and tuberculin 
syringe.15 Animals in the sham group received no intracisternal injection. All rats 
were kept in a prone position until they were euthanized using ether anesthesia 1 hour 
after intracisternal catheterization or carrageenan injection.
Tissue Processing, Histology, and Immunohistochemistry
At the end of the experiment, brain tissue was removed from the rats. Tissue 
samples were fixed in 10% formalin in phosphate buffer, processed using routine 
histologic methods, and embedded in paraffin blocks. Sections were cut using a mi-
crotome (RM2255, Leica Microsystems GmbH, Wetzlar, Germany). eNOS, nNOS, 
and iNOS immunohistochemistry was performed using anti-eNOS (Genetex Inc., 
Irvine, California), anti-nNOS (Genetex Inc.), and anti-iNOS (StressGen Biotechnolo-
gies Corporation, San Diego, California) antibodies. Sections were deparaffinized in 
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xylene and rehydrated through a graded ethanol series. They were then treated with 
2% trypsin at 37°C for 15 minutes. Sections were incubated in a solution of 3% hy-
drogen peroxide for 15 minutes to inhibit endogenous peroxidase activity. The sec-
tions were incubated overnight with anti-eNOS and anti-nNOS antibodies and then 
for another 30 minutes with biotinylated mouse secondary antibody. The bound sec-
ondary antibody was then amplified using an avidin:biotinylated enzyme complex kit 
(Vectastain ABC kit, Vector Laboratories, Burlingame, California). The antibody-
biotin-avidin-peroxidase complexes were visualized using 0.02% diaminobenzidine, 
and nuclei were counterstained with Harris hematoxylin. The sections were mounted 
onto lysine-coated slides. The images were analyzed using a computer-assisted image 
analyzer system consisting of a microscope (BX-50, Olympus, Tokyo, Japan) equipped 
with a high-resolution video camera (TK-890E, JVC, Tokyo, Japan). The immunola-
beling scores were evaluated blindly. Immunolabeling intensity was graded as fol-
lows: 1 = mild; 2 = moderate; 3 = strong; and 4 = very strong.16
Statistical Analysis
All statistical analyses were performed using SPSS software version 15 (SPSS Inc., 
Chicago, Illinois). Results are presented as mean (SD). Group differences were analyzed 
using the Mann-Whitney U test. P < 0.05 was considered statistically significant.
RESULTS
Three groups of 7 rats (weight range, 66–115 g) were used to conduct the study. The 
figure shows the staining for eNOS, nNOS and iNOS by immunohistochemistry in 
the brain stem of the rats.
The mean (SD) immunolabeling intensities for eNOS, nNOS, and iNOS in the 
brain stem of the study group were 2.85 (0.37), 2.42 (0.53), and 2.57 (0.53), respec-
tively; in the sham group they were 1.14 (0.37), 1.28 (0.48), and 1.28 (0.48); and in 
the control group they were 3.42 (0.53), 3.42 (0.78), and 3.71 (0.48) (Table).
The mean immunolabeling intensities for eNOS, nNOS, and iNOS enzymes in 
the brain stem were statistically significantly lower in the sham group compared with 
the control group (P = 0.001, P = 0.002, and P = 0.001, respectively). The mean 
values of the immunolabeling intensities for eNOS, nNOS, and iNOS were statisti-
cally significantly lower in the study group compared with the control group (P = 
0.001, P = 0.025, and P = 0.005, respectively).
DISCUSSION
Experimental models are helpful in advancing the understanding of the pathophysiol-
ogy of primary headaches and in developing new therapeutic approaches.17 Iatrogenic 
chemical stimulation of the meninges has been used to produce head pain.17 Carra-
geenan, a sulfated polysaccharide, promotes inflammation by activating proinflamma-
tory cells. It is used as an algesic agent in experimental studies.18 The experimental 
method we used in our study was reported previously by Nozaki et al.15 They injected 
carrageenan into the cisterna magna of anesthetized rats and reported that chemical 
stimulation of the meninges induced c-fos expression, a marker of nociception. 
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Table.  The immunolabeling intensities of the nitric oxide synthase 
(NOS) enzymes in the brain stem of adolescent male Wistar rats 
(N = 21). Data are mean (SD).
 Study Group* Sham Group† Control Group‡ 
NOS (n = 7) (n = 7) (n = 7)
eNOS 2.85 (0.37)§ 1.14 (0.37)§ 3.42 (0.53)
nNOS 2.42 (0.53)< 1.28 (0.48)¶ 3.42 (0.78)
iNOS 2.57 (0.53)# 1.28 (0.48)§ 3.71 (0.48)
eNOS = endothelial NOS; nNOS = neuronal NOS; iNOS = inducible NOS.
* Treated with sumatriptan succinate 2 hours before intracisternal carrageenan 
  injection.
† Not administered intracisternal carrageenan injection or sumatriptan pretreatment.
‡    Administered intracisternal carrageenan injection but not pretreated with 
  sumatriptan.
§  P = 0.001 versus control group.
<    P = 0.025 versus control group.
¶   P = 0.002 versus control group.
#  P = 0.005 versus control group.
eNOS
nNOS
iNOS
Study
Group
Sham
Group
Control
Group
Figure.  Photomicrographs showing immunolabeling of endothelial nitric oxide synthase 
(eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS) in the brain stem of ado-
lescent rats. Significant positive immunolabeling was detectable in tissues from 
the control group, and slight immunolabeling was detectable in tissues from the 
study group (Harris hematoxylin stain; original magnification, 20X).
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We applied this method to adolescent rats. Experimental studies of migraine 
pathophysiology have been performed in adult animals,8,10,15,17 and there are no data 
about the pathophysiology of primary headaches in adolescent animals. We propose 
that our findings in adolescent rats may be helpful in understanding the complex 
pathophysiology of primary headaches. Further studies are also needed to investigate 
the pathophysiology of primary headaches in adult and adolescent animals.
NO can induce headache in migraine patients and often triggers a delayed mi-
graine.5 The initial headache is thought to be caused via direct action of the NO-cyclic 
guanosine monophosphate pathway that causes vasodilatation by vascular smooth 
muscle relaxation, while the delayed headache is likely to be a result of triggering 
trigeminovascular activation.6 It has been demonstrated that the increased nNOS 
activity in the trigeminal system causes CGRP release and dural vessel dilation.7 
nNOS inhibitors were reported to partially inhibit neurogenic dural vasodilatation, 
while eNOS inhibitors were able to partially inhibit CGRP-induced dilatation.12 Our 
study did not show that sumatriptan was associated with the inhibition of neurogenic 
meningeal dural vasodilatation. However, it found that intracisternal injection of car-
rageenan was associated with a statistically significant increase in the production of 
NOS enzymes in the brain stem of adolescent rats and that sumatriptan was associated 
with an attenuation of the increase in the NOS enzymes observed after the administra-
tion of carrageenan. These results indicate the participation of NOS enzymes in primary 
headache pathophysiology and support the opinion that specific NOS-enzyme inhibitors 
might serve as pharmacologic agents to treat primary headaches in the future.2
A significant result of our study is that the increased NOS production in the brain 
stem might be antagonized by pretreatment with sumatriptan. These data suggest 
new therapeutic strategies for multitargeted combination drugs, including NOS 
inhibitors, to alleviate primary headache.
Although the experimental model in our study is useful for studying characteristics 
of trigeminal nociception, we did not conclude that the pathophysiology in this 
model is identical to the pathophysiology of human migraine headaches. 
CONCLUSIONS
In this experimental model of migraine in adolescent rats, intracisternal injection of 
carrageenan was associated with a significant increase in the production of NOS en-
zymes in the brain stem. Pretreatment with sumatriptan was associated with a de-
crease in NOS production.
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